Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
EU WC
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. 3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-c-(hydroxymethyl)-d-epi-inositol
2. Basen
3. N-(1,3-dihydroxy-2-propyl)valiolamine
1. 83480-29-9
2. Basen
3. Glustat
4. Ao-128
5. Ao 128
6. A-71100
7. (1s,2s,3r,4s,5s)-5-((1,3-dihydroxypropan-2-yl)amino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
8. Chembl476960
9. S77p977ag8
10. 3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-c-(hydroxymethyl)-d-epi-inositol
11. Dsstox_cid_1442
12. Dsstox_rid_76161
13. Dsstox_gsid_21442
14. (1s,2s,3r,4s,5s)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
15. (1s,2s,3r,4s,5s)-5-[(1,3-dihydroxypropan-2-yl)amino]-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
16. Voglibosum
17. Basen Od
18. Voglibose [inn]
19. 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-c-(hydroxymethyl)-d-epinositol
20. Cas-83480-29-9
21. Basen (tn)
22. Voglibose [usan:inn]
23. Voglibosum [inn-latin]
24. Voglibosa [inn-spanish]
25. N-(1,3-dihydroxy-2-propyl)valiolamine
26. Unii-s77p977ag8
27. Ccris 4540
28. Ncgc00164595-01
29. Voglibose- Bio-x
30. 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-c-(hydroxymethyl)-d-epi-inositol
31. Vog
32. Voglibose [jan]
33. Voglibose [mi]
34. Voglibose [usan]
35. Voglibose [mart.]
36. Schembl5882
37. Voglibose [who-dd]
38. A 71100
39. (1s,2s,3r,4s,5s)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
40. Mls003882582
41. Voglibose (jp17/usan/inn)
42. Dtxsid2021442
43. Chebi:32300
44. Bcpp000020
45. Dtxsid501031239
46. Hms3414a17
47. Hms3678a17
48. Voglibose, >=97.0% (tlc)
49. 112653-29-9
50. Hy-b0025
51. Zinc3788703
52. Tox21_112220
53. Bdbm50263044
54. S4101
55. Akos015950839
56. Tox21_112220_1
57. Ccg-267119
58. Db04878
59. Ncgc00164595-02
60. (1s,2s,3r,4s,5s)-5-{[2-hydroxy-1-(hydroxymethyl)ethyl]amino}-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol
61. Bv164530
62. Smr002530327
63. A25630
64. D01665
65. Ab01566929_01
66. 480v299
67. Sr-01000883931
68. Q-101310
69. Q7939403
70. Sr-01000883931-1
71. Brd-k66850609-001-01-7
72. Brd-k66850609-001-07-4
73. (1r,2r,3s,4r,5r)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
74. D-epi-inositol, 3,4-dideoxy-4-((2-hydroxy-1-(hydroxymethyl)ethyl)amino)-2-c-(hydroxymethyl)-
Molecular Weight | 267.28 g/mol |
---|---|
Molecular Formula | C10H21NO7 |
XLogP3 | -4.1 |
Hydrogen Bond Donor Count | 8 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 5 |
Exact Mass | 267.13180201 g/mol |
Monoisotopic Mass | 267.13180201 g/mol |
Topological Polar Surface Area | 154 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 263 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 5 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For the treatment of diabetes. It is specifically used for lowering post-prandial blood glucose levels thereby reducing the risk of macrovascular complications.
Voglibose, an alpha-glucosidase inhibitor, is a synthetic compound with potent and enduring therapeutic efficacies against disorders of sensory, motor and autonomic nerve systems due to diabetes mellitus. The drug was approved in Japan in 1994 for the treatment of diabetes, and it is under further investigation by Takeda for the treatment of impaired glucose tolerance. Alpha-glucosidase inhibitors are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of complex carbohydrates (such as starch). Complex carbohydrates are normally converted into simple sugars (monosaccharides) which can be absorbed through the intestine. Hence, alpha-glucosidase inhibitors reduce the impact of complex carbohydrates on blood sugar.
Hypoglycemic Agents
Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)
Glycoside Hydrolase Inhibitors
Compounds that inhibit or block the activity of GLYCOSIDE HYDROLASES such as ALPHA-AMYLASES and ALPHA-GLUCOSIDASES. (See all compounds classified as Glycoside Hydrolase Inhibitors.)
A - Alimentary tract and metabolism
A10 - Drugs used in diabetes
A10B - Blood glucose lowering drugs, excl. insulins
A10BF - Alpha glucosidase inhibitors
A10BF03 - Voglibose
Absorption
Slowly and poorly absorbed. The reported pharmacokinetic parameters of voglibose with metformin are Cmax corresponds to 1.38 mcg/ml while AUC is 8.17 mcg.h/ml and tmax is of 2.5 hours.
Little metabolism occurs and no metabolites have as yet been identified.
The half-life of voglibose is very similar to the one found for metformin and it is reported to be of 4.08 hours.
Alpha-glucosidase inhibitors are saccharides that act as competitive inhibitors of enzymes needed to digest carbohydrates: specifically alpha-glucosidase enzymes in the brush border of the small intestines. The membrane-bound intestinal alpha-glucosidases hydrolyze oligosaccharides, trisaccharides, and disaccharides to glucose and other monosaccharides in the small intestine. Acarbose also blocks pancreatic alpha-amylase in addition to inhibiting membrane-bound alpha-glucosidases. Pancreatic alpha-amylase hydrolyzes complex starches to oligosaccharides in the lumen of the small intestine. Inhibition of these enzyme systems reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. In diabetic patients, the short-term effect of these drugs therapies is to decrease current blood glucose levels: the long term effect is a small reduction in hemoglobin-A1c level. (From Drug Therapy in Nursing, 2nd ed)
Registration Number : 229MF10143
Registrant's Address : No. 1688 Shixian Road, Jining City, Shandong Province
Initial Date of Registration : 2017-07-25
Latest Date of Registration : 2017-07-25
Japanese Pharmacopoeia Voglibose
Registration Number : 223MF10028
Registrant's Address : 500, Sinnae-ro, Geumwang-eup, Eumseong-gun, Chungcheongbuk-do, Korea
Initial Date of Registration : 2011-02-25
Latest Date of Registration : 2019-05-08
Registration Number : 226MF10227
Registrant's Address : 343, Sapyeong-daero, Seocho-gu, Seoul, Korea
Initial Date of Registration : 2014-12-08
Latest Date of Registration : 2014-12-08
Registration Number : 303MF10056
Registrant's Address : 110, MAGOKDONG-RO, GANGSEO-GU, SEOUL, KOREA
Initial Date of Registration : 2021-03-30
Latest Date of Registration : 2024-03-27
Registration Number : 222MF10132
Registrant's Address : 110, MAGOKDONG-RO, GANGSEO-GU, SEOUL, KOREA
Initial Date of Registration : 2010-04-12
Latest Date of Registration : 2010-04-12
Registration Number : 227MF10165
Registrant's Address : No. 9, Minpu Road, Qingyang, Jiangyin, Wuxi, Jiangsu, 214401 China
Initial Date of Registration : 2015-06-18
Latest Date of Registration : 2015-06-18
Registration Number : 224MF10201
Registrant's Address : Plot No. 90, Sector 32, Gurgaon, Haryana 122 001, India
Initial Date of Registration : 2012-10-03
Latest Date of Registration : 2012-10-03
Registration Number : 227MF10108
Registrant's Address : No. 4258 Jindu Road, Shanghai, China
Initial Date of Registration : 2015-04-09
Latest Date of Registration : 2015-04-09
Registration Number : 217MF10861
Registrant's Address : Osaka Prefecture, Osaka City, Suminoe Ward, Nanko Kita 1-19-40
Initial Date of Registration : 2005-11-01
Latest Date of Registration : 2010-01-07
Registration Number : 302MF10094
Registrant's Address : No. 100 Waisha Branch Rd. , Jiaojiang, Taizhou, Zhejiang, China
Initial Date of Registration : 2020-08-05
Latest Date of Registration : 2021-04-27
Registrant Name : HKINNOEN Co., Ltd.
Registration Date : 2021-05-17
Registration Number : 20210517-209-J-756
Manufacturer Name : Hamari PFST, Ltd.
Manufacturer Address : 2-4300-18, Hachimampara, Yonezawa, Yamagata, Japan
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
About the Company : Allastir instituted the services in 2010 with a motive to cater the pharmaceutical industry with niche API's. In Allastir we strongly believe in team work and customer satisfaction...
About the Company : Anthem Biosciences is a leading contract research and innovation service provider (CRISP) in Bengaluru, India, which manufactures novel drug actives. Established in 2007, it specia...
About the Company : Aspire group was established in the year 2000 with a motto of quality drug for better health of all. In its journey till date, aspire has developed enormous reputation, consistent ...
About the Company : Dalian Richon Chem. Co., Ltd is a high-tech enterprise professionally involved in research and development, manufacturing process and sales service of pharmaceutical intermediates ...
About the Company : HANGZHOU THINK CHEMICAL CO., LTD. (THINKCHEM) is an integrative corporation of trade, research and contract manufacture. With about ten years of business experiences on the marketi...
About the Company : Public health is always an imperative that implies immense responsibility, not a mere re-adjustable option. As a company operating under world’s second largest industry of Pharma...
About the Company : Venkata Narayana Active Ingredients (Formerly Nutra Specialties Private Limited) Promoted by a well-known business house of India, Mr. Abhaya Kumar Jain who has vast experience in ...
About the Company : Further Pharmaceutical (www.further-pharm.com) is an innovation-driven and service-oriented biopharmaceutical company with global operations that develops and manufactures specialt...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info : Generic
Registration Country : India
Brand Name : Glyvog
Dosage Form : Tablet
Dosage Strength : 0.2MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Regulatory Info : Generic
Registration Country : India
Brand Name : Glyvog
Dosage Form : Tablet
Dosage Strength : 0.3MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Regulatory Info : Generic
Registration Country : India
Voglibose; Sitagliptin Phosphate
Brand Name : VOGLIEON-M2
Dosage Form : BILAYERED TABLET
Dosage Strength : 0.2MG; 500MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Generic
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 0.2MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info : Commercialized In: India (2011); Countries Registered In: India (2011)
Registration Country : India
Metformin Hydrochloride; voglibose
Brand Name :
Dosage Form : Sustained Release Tablet
Dosage Strength : 500MG; 0.2MG
Packaging :
Approval Date :
Application Number :
Regulatory Info : Commercialized In: India (2011); Countries Registered In: India (2011)
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Tablet
Dosage Strength : 0.3MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Uncoated Tablet
Dosage Strength : 0.2MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Regulatory Info :
Registration Country : China
Brand Name :
Dosage Form : Capsule
Dosage Strength : 0.2MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : China
Regulatory Info :
Registration Country : China
Brand Name :
Dosage Form : Capsule
Dosage Strength : 0.2MG
Packaging : 0.2mgx10caps; 0.2mgx10capsx5plates
Approval Date :
Application Number :
Regulatory Info :
Registration Country : China
Regulatory Info :
Registration Country : India
Brand Name :
Dosage Form : Orally Disintegrating Tablet
Dosage Strength : 0.2MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : India
Global Sales Information
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Voglibose manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Voglibose, including repackagers and relabelers. The FDA regulates Voglibose manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Voglibose API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Voglibose manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Voglibose supplier is an individual or a company that provides Voglibose active pharmaceutical ingredient (API) or Voglibose finished formulations upon request. The Voglibose suppliers may include Voglibose API manufacturers, exporters, distributors and traders.
click here to find a list of Voglibose suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Voglibose Drug Master File in Japan (Voglibose JDMF) empowers Voglibose API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Voglibose JDMF during the approval evaluation for pharmaceutical products. At the time of Voglibose JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Voglibose suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Voglibose Drug Master File in Korea (Voglibose KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Voglibose. The MFDS reviews the Voglibose KDMF as part of the drug registration process and uses the information provided in the Voglibose KDMF to evaluate the safety and efficacy of the drug.
After submitting a Voglibose KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Voglibose API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Voglibose suppliers with KDMF on PharmaCompass.
Voglibose Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Voglibose GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Voglibose GMP manufacturer or Voglibose GMP API supplier for your needs.
A Voglibose CoA (Certificate of Analysis) is a formal document that attests to Voglibose's compliance with Voglibose specifications and serves as a tool for batch-level quality control.
Voglibose CoA mostly includes findings from lab analyses of a specific batch. For each Voglibose CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Voglibose may be tested according to a variety of international standards, such as European Pharmacopoeia (Voglibose EP), Voglibose JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Voglibose USP).
LOOKING FOR A SUPPLIER?